Savolitinib Plus Osimertinib: A Promising Oral Combination for MET-Driven Resistance in EGFR-Mutated Advanced NSCLC – Insights from the SAVANNAH Phase II Study
MET-driven resistance is a frequent mechanism after first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Savolitinib plus osimertinib achieved an objective response rate (ORR) exceeding 55% in patients with high MET overexpression/amplification post-osimertinib.
The combination showed a median progression-free survival (PFS) of 7.4–7.5 months and was generally well tolerated.
This regimen may establish a new oral standard for targeting MET-driven resistance following EGFR TKI therapy.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.